Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Joseph Saseen

Concepts (461)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
29
2025
449
5.260
 Why?
Atherosclerosis
9
2025
402
3.480
 Why?
Cardiovascular Diseases
24
2025
2082
2.930
 Why?
Cholesterol, LDL
15
2025
360
2.890
 Why?
Pharmacists
18
2025
255
2.850
 Why?
Hypertension
23
2024
1251
2.790
 Why?
Antihypertensive Agents
14
2024
507
2.630
 Why?
Hypercholesterolemia
9
2025
101
1.890
 Why?
Students, Pharmacy
8
2025
101
1.830
 Why?
Educational Measurement
6
2025
315
1.580
 Why?
Education, Pharmacy
8
2025
126
1.550
 Why?
Hypolipidemic Agents
8
2021
92
1.420
 Why?
Blood Pressure
12
2024
1745
1.400
 Why?
Anticholesteremic Agents
8
2025
153
1.370
 Why?
Professional Role
7
2020
164
1.360
 Why?
Practice Patterns, Physicians'
6
2025
1328
1.360
 Why?
Dyslipidemias
8
2025
175
1.350
 Why?
Medication Therapy Management
5
2018
78
1.190
 Why?
Practice Guidelines as Topic
12
2020
1536
1.190
 Why?
Cholesterol
5
2020
404
1.060
 Why?
Lipids
3
2022
689
1.050
 Why?
Calcium Channel Blockers
7
2015
171
1.020
 Why?
Ambulatory Care
9
2018
584
1.020
 Why?
Managed Care Programs
4
2014
140
1.010
 Why?
Humans
141
2026
140898
0.960
 Why?
Gout
4
2025
38
0.940
 Why?
Societies, Pharmaceutical
7
2017
21
0.930
 Why?
Renal Insufficiency, Chronic
2
2025
622
0.900
 Why?
Chlorthalidone
2
2014
5
0.900
 Why?
Hydrochlorothiazide
2
2014
9
0.900
 Why?
Pharmaceutical Services
5
2020
83
0.880
 Why?
Arthritis, Gouty
2
2016
15
0.880
 Why?
Retrospective Studies
38
2025
16315
0.870
 Why?
Adrenergic beta-Antagonists
4
2014
228
0.840
 Why?
Anti-Inflammatory Agents, Non-Steroidal
5
2018
348
0.820
 Why?
Education, Pharmacy, Graduate
4
2017
16
0.800
 Why?
Aged
42
2025
24666
0.790
 Why?
Urinary Tract Infections
2
2023
193
0.790
 Why?
Pharmacy Residencies
3
2018
11
0.790
 Why?
American Heart Association
4
2020
296
0.770
 Why?
Dicarboxylic Acids
2
2025
12
0.760
 Why?
Diabetes Mellitus
4
2023
1072
0.750
 Why?
Middle Aged
46
2026
34487
0.740
 Why?
Primary Health Care
10
2025
1756
0.730
 Why?
Blood Glucose
4
2017
2273
0.710
 Why?
Clinical Competence
4
2018
1196
0.710
 Why?
Diuretics
4
2014
72
0.700
 Why?
Evidence-Based Medicine
14
2018
712
0.700
 Why?
Coronary Artery Disease
3
2021
702
0.690
 Why?
Serotonin 5-HT1 Receptor Agonists
1
2020
4
0.690
 Why?
Preceptorship
2
2018
68
0.690
 Why?
Angiotensin-Converting Enzyme Inhibitors
5
2011
197
0.680
 Why?
Drug Prescriptions
2
2020
263
0.670
 Why?
Gout Suppressants
3
2025
21
0.650
 Why?
Diabetes Mellitus, Type 2
7
2022
2524
0.650
 Why?
Teaching
3
2018
233
0.650
 Why?
Muscular Diseases
2
2015
113
0.630
 Why?
Hypoglycemic Agents
4
2014
1368
0.620
 Why?
Proton Pump Inhibitors
2
2024
109
0.610
 Why?
Migraine Disorders
1
2020
106
0.610
 Why?
Fatty Acids
2
2025
448
0.600
 Why?
Health Benefit Plans, Employee
2
2017
27
0.590
 Why?
Aged, 80 and over
17
2025
7899
0.590
 Why?
Emergency Service, Hospital
2
2020
2190
0.580
 Why?
Drug Therapy
2
2017
81
0.580
 Why?
Female
57
2026
75540
0.560
 Why?
Male
52
2026
69893
0.560
 Why?
Acetaminophen
3
2007
264
0.560
 Why?
Text Messaging
3
2025
179
0.550
 Why?
Insurance Coverage
2
2011
239
0.550
 Why?
Simvastatin
3
2015
62
0.530
 Why?
Primary Prevention
4
2025
201
0.530
 Why?
Faculty, Pharmacy
1
2017
20
0.510
 Why?
Adult
35
2026
39134
0.510
 Why?
Schools, Pharmacy
1
2017
48
0.510
 Why?
Research
2
2017
431
0.500
 Why?
Population Health
1
2017
45
0.490
 Why?
HIV
1
2017
247
0.490
 Why?
Cardiology
4
2018
279
0.480
 Why?
Heart Failure
3
2023
2093
0.460
 Why?
Hyperlipidemias
5
2018
125
0.460
 Why?
Antipsychotic Agents
1
2017
208
0.460
 Why?
Anti-Retroviral Agents
1
2017
240
0.460
 Why?
Monitoring, Physiologic
1
2017
285
0.460
 Why?
Perception
1
2018
375
0.460
 Why?
Treatment Outcome
18
2025
11125
0.440
 Why?
Proprotein Convertase 9
5
2025
87
0.440
 Why?
Faculty, Medical
1
2017
292
0.430
 Why?
Angiotensin II Type 1 Receptor Blockers
2
2013
38
0.430
 Why?
Poverty
2
2008
527
0.420
 Why?
United States
24
2025
15195
0.420
 Why?
Program Evaluation
3
2017
919
0.420
 Why?
Analgesics, Non-Narcotic
2
2007
127
0.420
 Why?
Gastrointestinal Hemorrhage
2
2024
134
0.420
 Why?
Aspirin
3
2024
384
0.410
 Why?
Risk Factors
18
2025
10430
0.410
 Why?
Drug Therapy, Combination
12
2020
1038
0.410
 Why?
Tetrazoles
1
2013
45
0.410
 Why?
Ezetimibe
4
2021
25
0.400
 Why?
Guideline Adherence
4
2025
553
0.400
 Why?
Colorado
14
2026
4597
0.400
 Why?
Xanthine Oxidase
3
2025
81
0.390
 Why?
Self Report
1
2017
858
0.390
 Why?
Adrenal Cortex Hormones
2
2016
501
0.390
 Why?
Gemfibrozil
3
2016
11
0.390
 Why?
Anti-Arrhythmia Agents
2
2003
112
0.390
 Why?
Glomerular Filtration Rate
3
2025
752
0.380
 Why?
Curriculum
6
2018
1029
0.380
 Why?
Osteoarthritis
2
2006
203
0.380
 Why?
Venoms
1
2012
28
0.380
 Why?
Imidazoles
1
2013
254
0.370
 Why?
Analgesics, Opioid
1
2020
1114
0.370
 Why?
Health Expenditures
5
2017
193
0.360
 Why?
Lipoprotein(a)
2
2022
68
0.350
 Why?
Problem-Based Learning
3
2017
96
0.350
 Why?
Kidney
1
2019
1475
0.350
 Why?
Health Resources
1
2012
127
0.340
 Why?
Medication Adherence
2
2025
510
0.340
 Why?
Electronic Health Records
5
2018
1125
0.340
 Why?
Medicare Part D
1
2011
25
0.340
 Why?
Risk Assessment
11
2022
3484
0.330
 Why?
Arthritis, Rheumatoid
3
2009
1178
0.310
 Why?
Insurance Claim Review
3
2017
85
0.310
 Why?
Azetidines
2
2008
46
0.310
 Why?
Young Adult
10
2025
13646
0.310
 Why?
Patient Care Team
5
2024
664
0.310
 Why?
Rosuvastatin Calcium
2
2025
21
0.300
 Why?
Societies, Medical
5
2025
852
0.300
 Why?
Drug Interactions
4
2022
403
0.300
 Why?
Reminder Systems
3
2025
174
0.290
 Why?
Prescription Drugs
2
2026
112
0.290
 Why?
Antirheumatic Agents
2
2009
298
0.290
 Why?
Clinical Trials as Topic
8
2017
1031
0.280
 Why?
Age Factors
5
2017
3278
0.280
 Why?
Community Health Centers
2
2018
63
0.280
 Why?
Antibodies, Monoclonal
4
2020
1471
0.280
 Why?
Consensus
4
2025
545
0.280
 Why?
Cohort Studies
10
2020
5789
0.270
 Why?
Drug Costs
2
2006
114
0.260
 Why?
Venous Thromboembolism
2
2022
336
0.260
 Why?
HIV Infections
2
2023
2967
0.260
 Why?
Platelet Aggregation Inhibitors
2
2024
475
0.260
 Why?
Verapamil
2
1997
40
0.260
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
48
0.260
 Why?
Family Practice
4
2015
440
0.260
 Why?
Tablets
1
2006
41
0.250
 Why?
Weight Loss
3
2012
790
0.250
 Why?
Liver Diseases, Alcoholic
1
2007
94
0.250
 Why?
Peptides
1
2012
979
0.250
 Why?
Kidney Failure, Chronic
2
2010
599
0.250
 Why?
Certification
2
2006
119
0.250
 Why?
Drug Utilization
2
2026
166
0.250
 Why?
Cyclooxygenase 2 Inhibitors
1
2006
22
0.250
 Why?
Renal Dialysis
1
2010
457
0.240
 Why?
Drug Compounding
1
2006
104
0.240
 Why?
Civil Defense
1
2026
22
0.240
 Why?
Sodium Chloride, Dietary
1
2006
31
0.240
 Why?
Lipoproteins
1
2007
163
0.240
 Why?
Randomized Controlled Trials as Topic
7
2007
1598
0.240
 Why?
Chemical and Drug Induced Liver Injury
2
2007
138
0.240
 Why?
Patient Care
3
2017
117
0.240
 Why?
Enzyme Inhibitors
2
2025
842
0.230
 Why?
Benzothiadiazines
1
2005
3
0.230
 Why?
Insurance, Health
4
2015
298
0.230
 Why?
Sodium Chloride Symporter Inhibitors
1
2005
9
0.230
 Why?
Ambulatory Care Facilities
2
2017
246
0.230
 Why?
Blood Pressure Determination
3
2018
145
0.230
 Why?
Education, Distance
1
2025
54
0.220
 Why?
Brain Ischemia
1
2008
349
0.220
 Why?
Drug Labeling
3
2015
38
0.220
 Why?
Quality Assurance, Health Care
1
2006
318
0.220
 Why?
Bronchiolitis, Viral
1
2004
11
0.210
 Why?
Fatty Acids, Omega-3
1
2025
142
0.210
 Why?
Adolescent
8
2025
22027
0.210
 Why?
Patient-Centered Care
3
2015
536
0.210
 Why?
Delivery of Health Care
4
2026
949
0.200
 Why?
Off-Label Use
2
2015
50
0.200
 Why?
Contraceptive Agents
1
2004
66
0.200
 Why?
Life Style
1
2006
478
0.200
 Why?
Epinephrine
1
2004
148
0.200
 Why?
Cardiovascular Agents
1
2025
156
0.200
 Why?
Progesterone Congeners
1
2003
15
0.200
 Why?
Medroxyprogesterone
1
2003
12
0.200
 Why?
Incidence
3
2023
2782
0.200
 Why?
Quality Indicators, Health Care
1
2005
304
0.200
 Why?
Hormone Replacement Therapy
1
2004
102
0.200
 Why?
Secondary Prevention
3
2024
240
0.190
 Why?
Estrogens, Conjugated (USP)
1
2003
51
0.190
 Why?
Bronchodilator Agents
1
2004
196
0.190
 Why?
Faculty
2
2018
153
0.190
 Why?
Health Knowledge, Attitudes, Practice
2
2025
1395
0.190
 Why?
C-Reactive Protein
1
2005
416
0.190
 Why?
Tumor Necrosis Factor-alpha
1
2007
1241
0.190
 Why?
Heart Conduction System
1
2003
89
0.190
 Why?
Program Development
2
2017
364
0.190
 Why?
Death, Sudden, Cardiac
1
2003
191
0.180
 Why?
Contraception
1
2004
165
0.180
 Why?
Estrogen Replacement Therapy
1
2003
142
0.180
 Why?
Attitude to Health
1
2005
451
0.180
 Why?
Antiphospholipid Syndrome
1
2021
31
0.180
 Why?
Artificial Intelligence
1
2025
332
0.180
 Why?
Atenolol
2
2014
8
0.170
 Why?
Communicable Diseases
1
2023
161
0.170
 Why?
Dietary Supplements
1
2025
566
0.170
 Why?
Vasodilator Agents
1
2003
330
0.170
 Why?
Uric Acid
2
2025
164
0.170
 Why?
Drug Tolerance
1
2021
105
0.170
 Why?
Pre-Exposure Prophylaxis
1
2023
237
0.160
 Why?
Public Health Administration
1
2021
74
0.160
 Why?
Costs and Cost Analysis
3
2014
219
0.160
 Why?
Diabetic Nephropathies
1
2004
293
0.160
 Why?
Transition to Adult Care
1
2022
92
0.160
 Why?
Dipyrone
1
1999
2
0.160
 Why?
Dose-Response Relationship, Drug
4
2014
2056
0.160
 Why?
Methenamine
1
2019
5
0.160
 Why?
Appetite Stimulants
1
1999
2
0.160
 Why?
HIV Wasting Syndrome
1
1999
4
0.160
 Why?
Pharmacy Service, Hospital
2
2013
84
0.160
 Why?
Diltiazem
2
1996
19
0.160
 Why?
Anabolic Agents
1
1999
13
0.160
 Why?
Anti-Infective Agents, Urinary
1
2019
17
0.160
 Why?
Nifedipine
2
1996
29
0.160
 Why?
Stroke
1
2008
1158
0.160
 Why?
Drug and Narcotic Control
1
1999
26
0.160
 Why?
Cross-Sectional Studies
4
2025
5645
0.160
 Why?
Heart Rate
1
2003
821
0.150
 Why?
Internship, Nonmedical
3
2011
13
0.150
 Why?
Patient Education as Topic
3
2024
772
0.150
 Why?
Protons
1
2019
93
0.150
 Why?
Atrial Fibrillation
1
2003
384
0.140
 Why?
Federal Government
1
2018
24
0.140
 Why?
Guidelines as Topic
2
2019
268
0.140
 Why?
Training Support
1
2018
36
0.140
 Why?
Health Services
2
2009
115
0.140
 Why?
Acquired Immunodeficiency Syndrome
1
1999
231
0.140
 Why?
Risk
2
2017
903
0.140
 Why?
Thrombosis
1
2021
398
0.130
 Why?
Medically Underserved Area
1
2018
99
0.130
 Why?
Surveys and Questionnaires
3
2025
5931
0.130
 Why?
Peripheral Arterial Disease
1
2024
490
0.130
 Why?
Models, Econometric
1
2017
36
0.130
 Why?
Quality of Health Care
2
2017
645
0.130
 Why?
Severity of Illness Index
3
2019
2898
0.130
 Why?
Vulnerable Populations
1
2018
170
0.130
 Why?
Anticoagulants
4
2022
674
0.130
 Why?
United States Food and Drug Administration
2
2015
197
0.130
 Why?
Colchicine
1
2016
23
0.130
 Why?
Protease Inhibitors
1
2017
104
0.130
 Why?
Warfarin
3
2021
153
0.130
 Why?
Hyperuricemia
1
2016
45
0.120
 Why?
Chronic Disease
3
2013
1811
0.120
 Why?
Anti-HIV Agents
1
2023
846
0.120
 Why?
Alcoholism
1
2003
821
0.120
 Why?
Point-of-Care Systems
1
2018
187
0.120
 Why?
Comorbidity
4
2016
1658
0.120
 Why?
Biomarkers
6
2025
4175
0.120
 Why?
Amlodipine
1
2015
10
0.110
 Why?
Pharmacovigilance
1
2015
24
0.110
 Why?
Education, Medical, Undergraduate
1
2017
195
0.110
 Why?
Liver
1
2003
1815
0.110
 Why?
Systole
1
2014
175
0.110
 Why?
Ethanolamines
1
2014
15
0.110
 Why?
Nebivolol
1
2014
10
0.110
 Why?
Metoprolol
1
2014
26
0.110
 Why?
Benzopyrans
1
2014
30
0.110
 Why?
Propanolamines
1
2014
39
0.110
 Why?
Exercise
1
2006
2108
0.100
 Why?
Carbazoles
1
2014
56
0.100
 Why?
Geriatrics
2
2025
93
0.100
 Why?
Risk Reduction Behavior
3
2022
226
0.100
 Why?
Losartan
1
2013
14
0.100
 Why?
Follow-Up Studies
3
2016
5194
0.100
 Why?
Valsartan
1
2013
30
0.100
 Why?
Valine
1
2013
77
0.100
 Why?
Medicaid
1
2017
446
0.100
 Why?
Drug Substitution
1
2013
60
0.100
 Why?
Biphenyl Compounds
1
2013
71
0.100
 Why?
Antidepressive Agents, Second-Generation
2
2004
48
0.100
 Why?
Fibric Acids
1
2012
3
0.090
 Why?
Contraindications
1
2012
85
0.090
 Why?
Socioeconomic Factors
1
2017
1310
0.090
 Why?
Drug Combinations
2
2016
365
0.090
 Why?
Telemedicine
1
2021
886
0.090
 Why?
Patient Acceptance of Health Care
2
2012
876
0.090
 Why?
Reproducibility of Results
3
2005
3336
0.090
 Why?
Age Distribution
1
2012
397
0.090
 Why?
Internship and Residency
2
2017
1222
0.090
 Why?
Double-Blind Method
4
2003
1978
0.090
 Why?
Vascular Endothelial Growth Factor A
1
2014
550
0.090
 Why?
Annual Reports as Topic
1
2010
3
0.090
 Why?
Professional Staff Committees
1
2010
12
0.090
 Why?
Decision Support Systems, Clinical
1
2015
263
0.090
 Why?
Financing, Personal
1
2011
28
0.090
 Why?
Sex Factors
1
2017
2051
0.080
 Why?
Insurance Benefits
1
2010
12
0.080
 Why?
Insurance, Pharmaceutical Services
1
2010
24
0.080
 Why?
Interpersonal Relations
1
2014
407
0.080
 Why?
Acute Kidney Injury
1
2018
820
0.080
 Why?
Pharmacy
1
2010
31
0.080
 Why?
Creatinine
1
2012
490
0.080
 Why?
Analysis of Variance
1
2012
1313
0.080
 Why?
Drug Utilization Review
2
2006
61
0.080
 Why?
Nutrition Surveys
2
2021
280
0.080
 Why?
Hyperlipoproteinemia Type II
2
2019
32
0.070
 Why?
Hypoglycemia
1
2014
467
0.070
 Why?
Dipyridamole
1
2008
29
0.070
 Why?
Ezetimibe, Simvastatin Drug Combination
1
2008
1
0.070
 Why?
Fluorobenzenes
1
2008
17
0.070
 Why?
Ticlopidine
1
2008
52
0.070
 Why?
Drug Administration Schedule
2
2007
766
0.070
 Why?
Internet
2
2025
682
0.070
 Why?
Abatacept
1
2007
56
0.070
 Why?
Ischemic Attack, Transient
1
2008
70
0.070
 Why?
Patient Compliance
3
2008
607
0.070
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2007
96
0.070
 Why?
Adamantane
1
2007
18
0.070
 Why?
Dipeptidyl Peptidase 4
1
2007
15
0.070
 Why?
Proportional Hazards Models
1
2011
1261
0.070
 Why?
Timolol
1
2007
15
0.070
 Why?
Propranolol
1
2007
45
0.070
 Why?
Contraception, Postcoital
1
2007
9
0.060
 Why?
Accreditation
1
2007
93
0.060
 Why?
Community Pharmacy Services
1
2007
47
0.060
 Why?
Hemorrhage
2
2022
760
0.060
 Why?
Levonorgestrel
1
2007
36
0.060
 Why?
Rituximab
1
2007
205
0.060
 Why?
Pyrrolidines
1
2007
109
0.060
 Why?
Specialty Boards
1
2006
39
0.060
 Why?
Anti-Ulcer Agents
1
2006
15
0.060
 Why?
Immunoconjugates
1
2007
125
0.060
 Why?
Nitriles
1
2007
188
0.060
 Why?
Cost Savings
1
2006
86
0.060
 Why?
Medication Errors
1
2006
96
0.060
 Why?
Safety Management
1
2006
126
0.060
 Why?
Interrupted Time Series Analysis
1
2026
72
0.060
 Why?
Case Management
1
2005
66
0.060
 Why?
Pandemics
2
2026
1643
0.060
 Why?
Pharmaceutical Preparations
1
2006
168
0.060
 Why?
Efficiency, Organizational
1
2005
137
0.060
 Why?
Benchmarking
1
2005
179
0.050
 Why?
Pyrimidines
1
2008
508
0.050
 Why?
Nephrology
1
2005
61
0.050
 Why?
Sulfonamides
1
2008
565
0.050
 Why?
Professional-Patient Relations
1
2005
151
0.050
 Why?
Albuterol
1
2004
75
0.050
 Why?
Coronary Disease
2
2003
370
0.050
 Why?
Rhabdomyolysis
1
2003
24
0.050
 Why?
Amiodarone
1
2003
27
0.050
 Why?
Child, Preschool
2
2017
11462
0.050
 Why?
Meta-Analysis as Topic
1
2004
166
0.050
 Why?
Longitudinal Studies
1
2011
2920
0.050
 Why?
Medicare
1
2009
806
0.050
 Why?
Disease Susceptibility
1
2005
352
0.050
 Why?
Liver Function Tests
1
2003
105
0.050
 Why?
Antineoplastic Agents
1
2014
2156
0.050
 Why?
Nocebo Effect
1
2022
4
0.050
 Why?
Endpoint Determination
1
2003
77
0.050
 Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2022
16
0.050
 Why?
Cyclohexanols
1
2002
11
0.050
 Why?
Vaginal Diseases
1
2002
19
0.050
 Why?
Information Dissemination
1
2004
209
0.050
 Why?
Delivery of Health Care, Integrated
2
2018
290
0.050
 Why?
Physician-Patient Relations
1
2006
580
0.040
 Why?
Women's Health
1
2004
308
0.040
 Why?
Sodium
1
2022
195
0.040
 Why?
Kidney Diseases
1
2005
408
0.040
 Why?
Academic Medical Centers
1
2024
527
0.040
 Why?
Vitamin K 1
1
2000
3
0.040
 Why?
Acute Disease
1
2004
1010
0.040
 Why?
Postmenopause
1
2003
369
0.040
 Why?
Symptom Flare Up
1
2020
38
0.040
 Why?
Medical Audit
2
2013
77
0.040
 Why?
Health Plan Implementation
1
2021
142
0.040
 Why?
Aftercare
1
2022
218
0.040
 Why?
Antifibrinolytic Agents
1
2000
57
0.040
 Why?
Liver Diseases
1
2003
301
0.040
 Why?
Europe
1
2020
406
0.040
 Why?
Patient Satisfaction
1
2004
690
0.040
 Why?
Rivaroxaban
1
2021
258
0.040
 Why?
Predictive Value of Tests
1
2005
2062
0.040
 Why?
Ibuprofen
1
1999
83
0.040
 Why?
Kidney Function Tests
1
2019
158
0.040
 Why?
Administration, Oral
1
2021
802
0.040
 Why?
Societies, Scientific
1
2019
50
0.040
 Why?
Drug Hypersensitivity
1
2000
94
0.040
 Why?
Neoplasms
1
2014
2718
0.040
 Why?
Blood Coagulation
1
2000
269
0.040
 Why?
Student Health Services
1
2018
16
0.040
 Why?
Child
2
2017
22313
0.040
 Why?
Software
1
2023
676
0.030
 Why?
Antiretroviral Therapy, Highly Active
1
1999
278
0.030
 Why?
Self Care
1
2000
392
0.030
 Why?
United States Department of Veterans Affairs
1
2022
711
0.030
 Why?
Glucose
1
2022
1031
0.030
 Why?
Hospitals
1
2022
694
0.030
 Why?
Homozygote
1
2017
201
0.030
 Why?
Felodipine
1
1996
4
0.030
 Why?
Receptors, Drug
1
1996
13
0.030
 Why?
Cost-Benefit Analysis
1
2019
609
0.030
 Why?
Public Health
1
2021
554
0.030
 Why?
Drug Monitoring
2
2010
398
0.030
 Why?
Polypharmacy
1
2016
89
0.030
 Why?
Calcium Channels
1
1996
156
0.030
 Why?
Patient Discharge
1
2022
930
0.030
 Why?
Cross-Over Studies
1
1997
577
0.030
 Why?
Myocardial Ischemia
1
1996
280
0.030
 Why?
Communication
2
2014
948
0.030
 Why?
Data Interpretation, Statistical
1
1996
374
0.030
 Why?
Pain
1
1999
776
0.030
 Why?
Regression Analysis
2
2009
1015
0.030
 Why?
Clinical Decision-Making
1
2016
339
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2019
908
0.020
 Why?
Infant
2
2004
9790
0.020
 Why?
Hemodynamics
1
1997
1100
0.020
 Why?
Comprehension
1
2014
182
0.020
 Why?
Adrenergic Antagonists
1
2011
6
0.020
 Why?
Educational Status
1
2014
462
0.020
 Why?
Phytotherapy
1
2011
82
0.020
 Why?
Health Planning Guidelines
1
2010
24
0.020
 Why?
Poisson Distribution
1
2010
76
0.020
 Why?
Prospective Studies
3
2015
7749
0.020
 Why?
Breast Neoplasms
1
2003
2235
0.020
 Why?
Likelihood Functions
1
2010
145
0.020
 Why?
Models, Organizational
1
2011
143
0.020
 Why?
Anti-Bacterial Agents
1
2000
1856
0.020
 Why?
Preferred Provider Organizations
1
2009
4
0.020
 Why?
Pilot Projects
1
2015
1815
0.020
 Why?
Transportation
1
2009
52
0.020
 Why?
Private Sector
1
2009
51
0.020
 Why?
Case-Control Studies
1
2016
3578
0.020
 Why?
Phenotype
1
2017
3172
0.020
 Why?
Infliximab
1
2009
111
0.020
 Why?
Interprofessional Relations
1
2011
282
0.020
 Why?
North America
1
2009
305
0.020
 Why?
Cooperative Behavior
1
2011
455
0.020
 Why?
Quality of Life
1
2019
3005
0.020
 Why?
Multivariate Analysis
1
2010
1496
0.020
 Why?
Organizational Policy
1
2006
76
0.020
 Why?
Professional Practice
1
2006
62
0.010
 Why?
Health Care Costs
1
2009
418
0.010
 Why?
Role
1
2005
30
0.010
 Why?
Time Factors
1
1996
6944
0.010
 Why?
Logistic Models
1
2010
2088
0.010
 Why?
Expert Testimony
1
2005
41
0.010
 Why?
Bone Diseases, Metabolic
1
2005
64
0.010
 Why?
Interdisciplinary Communication
1
2005
191
0.010
 Why?
Review Literature as Topic
1
2004
48
0.010
 Why?
Diabetes Complications
1
2005
222
0.010
 Why?
Models, Economic
1
2004
60
0.010
 Why?
Probability
1
2004
308
0.010
 Why?
Venlafaxine Hydrochloride
1
2002
13
0.010
 Why?
Menstruation
1
2002
42
0.010
 Why?
International Normalized Ratio
1
2000
48
0.010
 Why?
Health Maintenance Organizations
1
2000
105
0.010
 Why?
beta-Lactams
1
2000
34
0.010
 Why?
Medical Records
1
2000
182
0.010
 Why?
Hospitalization
1
2009
2261
0.010
 Why?
Depressive Disorder
1
2002
374
0.010
 Why?
Sensitivity and Specificity
1
2004
1968
0.010
 Why?
Prevalence
1
2005
2780
0.010
 Why?
Depression
1
2004
1487
0.010
 Why?
Saseen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (461) concept(s)
_
Co-Authors Expand Description
See all (54) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)